Blast crisis is the final phase in the evolution of CML,.
In this phase CML behaves like an acute leukemia,
- rapid progression
- short survival.
|BLAST CRISIS – DIAGNOSIS||Any of the following present in CML|
|1||20% blasts in the blood or bone marrow|
|2||Extramedullary proliferation of blasts|
|Imatinib||Useful in Blast crisis of CML|
|inhibitor targeted at the BCR-ABL tyrosine kinase|
|BCR-ABL expression can be reduced by imatinib to very low or nondetectable levels|
|Median survival in chronic phase is estimated at a median of 25 to 30 years.|
|BC has been reduced to 1% to 1.5% per year|
Chronic myelogenous leukemia
Imatinib – inhibitor targeted at the BCR-ABL tyrosine kinase
Imatinib – has fundamentally changed treatment of CML.
BCR-ABL expression can be reduced by imatinib to very low or nondetectable levels in the majority of patients.
Median survival in chronic phase is estimated at a median of 25 to 30 years.
Progress to advanced phase CML or BC has been reduced to 1% to 1.5% per year
|Blast Crisis Symptoms|
|5||symptoms of anemia|
Blast crisis is associated with – additional cytogenetic aberrations (ACAs) in addition to the Philadelphia (Ph)–chromosome.
|Blast crisis is associated with – additional cytogenetic aberrations with Philadelphia (Ph)–chromosome|
Most frequent are the so called “major route” ACA
which are nonrandom and considered relevant for the pathogenesis of BC